Neurology

Back to articles

Monoamine oxidase inhibitors approved for Parkinson disease

KEY POINT

Rasagiline (Azilect—Teva Neuroscience), a monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine, was recently approved by FDA as once-daily monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced Parkinson disease. Rasagiline is taken once daily, and 0.5 and 1 mg tablets should be available by August. Separately, a new formulation of selegiline (Zelapar Orally Disintegrating Tablets–Valeant Pharmaceuticals), also an MAO-B inhibitor, has been approved by FDA as once-daily adjunct therapy to levodopa in moderate-to-advanced Parkinson disease. Zelapar will be available as 1.25 mg tablets.